Sandmann Lisa, Ohlendorf Valerie, Ehrenbauer Alena, Bremer Birgit, Kraft Anke R M, Cornberg Markus, Deterding Katja, Wedemeyer Heiner, Maasoumy Benjamin
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hanover, Germany.
D-SOLVE Consortium, an EU Horizon Europe Funded Project, partner site Hannover, Germany.
Liver Int. 2025 Feb;45(2):e70003. doi: 10.1111/liv.70003.
Chronic hepatitis D virus (HDV) infection can cause severe liver disease. With new treatment options available, it is important to identify patients at risk for liver-related complications. We aimed to investigate kinetics and predictive values of novel virological and immunological markers in the natural course of chronic HDV infection.
HBcrAg, HBV RNA and quantitative anti-HBc were analysed in samples from HDV-infected patients at three consecutive time points. Results were linked to clinical outcome by univariable and multivariable analyses. Primary endpoint was the composite endpoint of any liver-related event.
Samples from 190 individual patients were analysed with a median clinical follow-up time of 2.69 (IQR 1.13-6.51) years. The majority of patients had cirrhosis (98/190, 52%), and the primary endpoint occurred in 33% (62/190). In univariable analysis, age, cirrhosis, lower quantitative anti-HBc, higher ratio of HBcrAg/anti-HBc and detectable HDV RNA were associated with the primary endpoint. In multivariable analysis, only the presence of liver cirrhosis (HR 7.74, p < 0.001) and age (1.06, p < 0.001) remained independently associated with the primary endpoint. Kinetics of virological parameters during follow-up were similar between the groups. Quantitative anti-HBc was significantly lower in patients with liver cirrhosis (687 (IQR 188-3388) IU/ml vs. 309 (IQR 82-924) IU/ml, p < 0.0004), and lower levels were independently associated with the development of the primary endpoint (HR 1.0, p = 0.014).
In chronic HDV infection, neither baseline values nor kinetics of HBV RNA, HBcrAg and anti-HBc were independently associated with clinical outcome, while stage of liver disease and age were predictors of liver-related events.
慢性丁型肝炎病毒(HDV)感染可导致严重肝脏疾病。鉴于有了新的治疗选择,识别有肝脏相关并发症风险的患者很重要。我们旨在研究慢性HDV感染自然病程中新型病毒学和免疫学标志物的动力学及预测价值。
对HDV感染患者的样本在三个连续时间点分析HBcrAg、HBV RNA和定量抗-HBc。通过单变量和多变量分析将结果与临床结局相关联。主要终点是任何肝脏相关事件的复合终点。
分析了190例个体患者的样本,临床随访时间中位数为2.69(四分位间距1.13 - 6.51)年。大多数患者有肝硬化(98/190,52%),主要终点发生在33%(62/190)的患者中。在单变量分析中,年龄、肝硬化、较低的定量抗-HBc、较高的HBcrAg/抗-HBc比值和可检测到的HDV RNA与主要终点相关。在多变量分析中,仅肝硬化的存在(风险比7.74,p < 0.001)和年龄(1.06,p < 0.001)仍与主要终点独立相关。随访期间病毒学参数的动力学在各组间相似。肝硬化患者的定量抗-HBc显著更低(687(四分位间距188 - 3388)IU/ml对309(四分位间距82 - 924)IU/ml,p < 0.0004),较低水平与主要终点的发生独立相关(风险比1.0,p = 0.014)。
在慢性HDV感染中,HBV RNA、HBcrAg和抗-HBc的基线值及动力学均与临床结局无独立相关性,而肝病阶段和年龄是肝脏相关事件的预测因素。